Janssen-Cilag宣布TAR-200和Cetrelimab neadjuvant疗法,大大提高了肌肉侵入性膀胱癌病理反应率。 Janssen-Cilag announces TAR-200 and cetrelimab neoadjuvant therapy significantly increases muscle-invasive bladder cancer pathological response rate.
詹森- 奇拉格国际NV宣布,新辅助治疗TAR-200和 cetrelimab显著增加了肌肉侵入性膀癌患者的病理完整反应率,与单独使用cetrelimab相比,其有效性几乎翻了一番. Janssen-Cilag International NV announced that neoadjuvant treatment with TAR-200 and cetrelimab significantly increases the pathological complete response rate in muscle-invasive bladder cancer patients, nearly doubling the effectiveness compared to cetrelimab alone. 本研究的重点是没有资格接受或拒绝在激进细胞切除前接受白金基化疗的病人。 This study focuses on patients ineligible for or refusing platinum-based chemotherapy before radical cystectomy. 目前正在进行的试验正在评估TAR-200在各种膀胱癌阶段的安全性和功效。 Ongoing trials are assessing TAR-200’s safety and efficacy in various bladder cancer stages.